JP2021501776A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501776A5 JP2021501776A5 JP2020524641A JP2020524641A JP2021501776A5 JP 2021501776 A5 JP2021501776 A5 JP 2021501776A5 JP 2020524641 A JP2020524641 A JP 2020524641A JP 2020524641 A JP2020524641 A JP 2020524641A JP 2021501776 A5 JP2021501776 A5 JP 2021501776A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- months
- drug
- drug conjugate
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 49
- 229940079593 drug Drugs 0.000 claims 24
- 239000000611 antibody drug conjugate Substances 0.000 claims 23
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 23
- 206010008342 Cervix carcinoma Diseases 0.000 claims 12
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 201000010881 cervical cancer Diseases 0.000 claims 12
- 229940124597 therapeutic agent Drugs 0.000 claims 11
- 230000002411 adverse Effects 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 10
- 229930012538 Paclitaxel Natural products 0.000 claims 5
- 229960001592 paclitaxel Drugs 0.000 claims 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 5
- 102000002262 Thromboplastin Human genes 0.000 claims 4
- 108010000499 Thromboplastin Proteins 0.000 claims 4
- 239000000562 conjugate Substances 0.000 claims 4
- 230000004083 survival effect Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 3
- 108010044540 auristatin Proteins 0.000 claims 3
- 108010093470 monomethyl auristatin E Proteins 0.000 claims 3
- 239000008177 pharmaceutical agent Substances 0.000 claims 3
- 206010010741 Conjunctivitis Diseases 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 229960000397 bevacizumab Drugs 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 190000008236 carboplatin Chemical compound 0.000 claims 2
- 229960005395 cetuximab Drugs 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229940115080 doxil Drugs 0.000 claims 2
- 239000003889 eye drop Substances 0.000 claims 2
- -1 ixavepyrone Chemical compound 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 238000009121 systemic therapy Methods 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 2
- 229960000303 topotecan Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 108010016626 Dipeptides Proteins 0.000 claims 1
- 206010061818 Disease progression Diseases 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 208000019025 Hypokalemia Diseases 0.000 claims 1
- 206010021036 Hyponatraemia Diseases 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 230000004596 appetite loss Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960002173 citrulline Drugs 0.000 claims 1
- 238000009109 curative therapy Methods 0.000 claims 1
- 230000006866 deterioration Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000005750 disease progression Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000001780 epistaxis Diseases 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 230000036541 health Effects 0.000 claims 1
- 229960003685 imatinib mesylate Drugs 0.000 claims 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 208000019017 loss of appetite Diseases 0.000 claims 1
- 235000021266 loss of appetite Nutrition 0.000 claims 1
- 230000001050 lubricating effect Effects 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 208000011309 nasal bleeding Diseases 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 1
- 229960005079 pemetrexed Drugs 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 208000024896 potassium deficiency disease Diseases 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000005526 vasoconstrictor agent Substances 0.000 claims 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 1
- 229960002066 vinorelbine Drugs 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023179215A JP2024009998A (ja) | 2017-11-02 | 2023-10-18 | 抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762580877P | 2017-11-02 | 2017-11-02 | |
| US62/580,877 | 2017-11-02 | ||
| PCT/US2018/058771 WO2019089973A1 (en) | 2017-11-02 | 2018-11-01 | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023179215A Division JP2024009998A (ja) | 2017-11-02 | 2023-10-18 | 抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021501776A JP2021501776A (ja) | 2021-01-21 |
| JP2021501776A5 true JP2021501776A5 (enExample) | 2021-12-02 |
Family
ID=66332366
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524641A Pending JP2021501776A (ja) | 2017-11-02 | 2018-11-01 | 抗組織因子抗体−薬物コンジュゲートおよびがんの治療におけるその使用 |
| JP2023179215A Pending JP2024009998A (ja) | 2017-11-02 | 2023-10-18 | 抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023179215A Pending JP2024009998A (ja) | 2017-11-02 | 2023-10-18 | 抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20210177987A1 (enExample) |
| EP (1) | EP3703757A4 (enExample) |
| JP (2) | JP2021501776A (enExample) |
| KR (2) | KR20200084874A (enExample) |
| CN (2) | CN111655290A (enExample) |
| AU (2) | AU2018358120A1 (enExample) |
| BR (1) | BR112020008593A2 (enExample) |
| CA (1) | CA3080137A1 (enExample) |
| EA (1) | EA202090741A1 (enExample) |
| IL (2) | IL312038A (enExample) |
| MX (1) | MX2020004265A (enExample) |
| SG (1) | SG11202003713TA (enExample) |
| UA (1) | UA129645C2 (enExample) |
| WO (1) | WO2019089973A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200118029A (ko) | 2018-01-04 | 2020-10-14 | 아이코닉 테라퓨틱스, 인코포레이티드 | 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법 |
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| TW202010755A (zh) | 2018-05-07 | 2020-03-16 | 丹麥商珍美寶股份有限公司 | 使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法 |
| EP3836950A4 (en) * | 2018-08-16 | 2022-04-06 | Genmab A/S | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| CN114222752B (zh) * | 2019-07-03 | 2025-11-14 | 埃克塞里艾克西斯公司 | 抗组织因子抗体-药物缀合物及相关方法 |
| BR112022008661A2 (pt) * | 2019-11-07 | 2022-07-19 | Genmab As | Método para tratar câncer em um sujeito, conjugado de anticorpo-fármaco que se liga ao fator de tecido, uso de um conjugado de anticorpo-fármaco, e, kit |
| CA3183898A1 (en) * | 2020-06-29 | 2022-01-06 | Genmab A/S | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer |
| WO2022198231A1 (en) | 2021-03-18 | 2022-09-22 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| WO2024255879A1 (en) * | 2023-06-15 | 2024-12-19 | Fortvita Biologics (Singapore) Pte. Ltd. | Formulation comprising antibody-drug conjugate targeting claudin18.2, method for preparing the same, and use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG164368A1 (en) * | 2005-07-18 | 2010-09-29 | Bipar Sciences Inc | Treatment of cancer |
| WO2007058935A2 (en) * | 2005-11-14 | 2007-05-24 | Bausch & Lomb Incorporated | Ophthalmic composition for dry eye therapy |
| UA109633C2 (uk) * | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
| SMT201700547T1 (it) * | 2010-06-15 | 2018-01-11 | Genmab As | Coniugati di farmaco anticorpo umano contro il fattore tissutale |
| WO2014177771A1 (en) * | 2013-05-02 | 2014-11-06 | Glykos Finland Oy | Conjugates of a glycoprotein or a glycan with a toxic payload |
| DK3347054T3 (da) * | 2015-09-11 | 2021-07-19 | Genmab As | Dosisregimer til anti-TF-antistoflægemiddelkonjugater |
| CN106938051B (zh) * | 2016-08-22 | 2019-10-11 | 复旦大学 | 靶向于组织因子的抗体-药物偶联物 |
-
2018
- 2018-11-01 EA EA202090741A patent/EA202090741A1/ru unknown
- 2018-11-01 UA UAA202002379A patent/UA129645C2/uk unknown
- 2018-11-01 US US16/760,373 patent/US20210177987A1/en not_active Abandoned
- 2018-11-01 KR KR1020207015385A patent/KR20200084874A/ko not_active Ceased
- 2018-11-01 JP JP2020524641A patent/JP2021501776A/ja active Pending
- 2018-11-01 IL IL312038A patent/IL312038A/en unknown
- 2018-11-01 SG SG11202003713TA patent/SG11202003713TA/en unknown
- 2018-11-01 EP EP18873409.9A patent/EP3703757A4/en active Pending
- 2018-11-01 WO PCT/US2018/058771 patent/WO2019089973A1/en not_active Ceased
- 2018-11-01 AU AU2018358120A patent/AU2018358120A1/en not_active Abandoned
- 2018-11-01 CN CN201880085128.9A patent/CN111655290A/zh active Pending
- 2018-11-01 IL IL274122A patent/IL274122B2/en unknown
- 2018-11-01 KR KR1020257009636A patent/KR20250044949A/ko active Pending
- 2018-11-01 MX MX2020004265A patent/MX2020004265A/es unknown
- 2018-11-01 BR BR112020008593-6A patent/BR112020008593A2/pt unknown
- 2018-11-01 CA CA3080137A patent/CA3080137A1/en active Pending
- 2018-11-01 CN CN202510188791.3A patent/CN119868579A/zh active Pending
-
2023
- 2023-08-17 US US18/451,780 patent/US20240252673A1/en active Pending
- 2023-10-18 JP JP2023179215A patent/JP2024009998A/ja active Pending
-
2024
- 2024-09-11 AU AU2024219631A patent/AU2024219631A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021501776A5 (enExample) | ||
| IL312038A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
| JP2017110002A5 (enExample) | ||
| JP2018527383A5 (enExample) | ||
| JP2011507932A5 (enExample) | ||
| RU2018111205A (ru) | Терапевтические комбинации, содержащие анти-folr1 иммуноконъюгаты | |
| JP2019031568A5 (enExample) | ||
| TW202440170A (zh) | 抗folr1免疫偶聯物與抗pd-1抗體之組合 | |
| JP2010520290A5 (enExample) | ||
| JP2015500822A5 (enExample) | ||
| IL307925A (en) | Combination of an anti-pd-1 antibody and an anti-tissue factor (tf) antibody-drug conjugate for use in the treatment of cancer | |
| CN112218662A (zh) | 抗cd37免疫缀合物给药方案 | |
| TW202330040A (zh) | 抗ｈｅｒ２抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| EP3896089A1 (en) | Use of il-15 protein complex joint pd-l1 antibody for treating tumor diseases | |
| JPWO2019173523A5 (enExample) | ||
| JPWO2019183253A5 (enExample) | ||
| TWI870592B (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| JPWO2019217457A5 (enExample) | ||
| JPWO2019217455A5 (enExample) | ||
| JPWO2020092210A5 (enExample) | ||
| JPWO2020037024A5 (enExample) | ||
| JPWO2019143607A5 (enExample) | ||
| TW202034925A (zh) | Ｃｄｋ４／６抑制劑聯合免疫治療在製備治療淋巴瘤的藥物中的用途 | |
| JPWO2021090272A5 (enExample) | ||
| CN110013552B (zh) | 抗pd-1抗体、吉西他滨和铂类药物联合治疗恶性胆道肿瘤的用途 |